A phase II trial of girentuximab in combination with low-dose interferon alpha-2a in patients with metastatic clear cell renal cell cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Girentuximab (Primary) ; Interferon alpha-2a
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Heidelberg Pharma AG; WILEX AG
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 19 Oct 2006 New trial record.